If you liked this article you might like

Why Gilead Can't Easily Copy Celgene's 'Partner Partner Partner' Deal-Making Playbook

Why Gilead Can't Easily Copy Celgene's 'Partner Partner Partner' Deal-Making Playbook

Morning Movers: BUD, VZ, CELG, GS

Morning Movers: BUD, VZ, CELG, GS

Celgene Can't Expand Revlimid Approval Into Non-Hodgkin Lymphoma Just Yet

Celgene Can't Expand Revlimid Approval Into Non-Hodgkin Lymphoma Just Yet

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week